Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269510 | 0.83 | ALDH1A1 (0.52) | LMNAHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3275099 | 0.83 | ALDH1A1 (0.56) | LMNAHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29323749 | 0.81 | ELANE (0.51) | LMNAHTTSMN1; SMN2ALDH1A1ELANE | |
| SCHEMBL21472366 | 0.80 | SMN1; SMN2 (0.43) | LMNAHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1232411 | 0.79 | PKM (0.67) | LMNAHTTSMN1; SMN2ALDH1A1ELANE | |
| SCHEMBL1436154 | 0.78 | ELANE (0.54) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| Butane SCHEMBL15309676 | 0.77 | ELANE (0.61) | LMNAHTTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL56436 | 0.77 | ELANE (0.69) | LMNAHTTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL3248031 | 0.77 | ALDH1A1 (0.50) | LMNASMN1; SMN2ALDH1A1TSHRELANE | |
| SCHEMBL7184942 | 0.76 | ELANE (0.53) | LMNAHTTSMN1; SMN2ALDH1A1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120146264-A1 | RESIN COMPOSITION FOR LASER ENGRAVING, RELIEF PRINTING PLATE PRECURSOR FOR LASER ENGRAVING AND PROCESS FOR PRODUCING SAME, AND PROCESS FOR MAKING RELIEF PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| EP-1972440-B1 | Negative lithographic printing plate precursor and lithographic printing method using the same | FUJIFILM CORP (JP) | 2010-06-23 | — | — | EP | disclosed |
| EP-2105298-A1 | Negative-working lithographic printing plate precursor and method of lithographic printing using same | Fujifilm Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-20080233516-A1 | NEGATIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AND LITHOGRAPHIC PRINTING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1972440-A2 | Negative lithographic printing plate precursor and lithographic printing method using the same | FUJIFILM Corporation (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120146264-A1 | RESIN COMPOSITION FOR LASER ENGRAVING, RELIEF PRINTING PLATE PRECURSOR FOR LASER ENGRAVING AND PROCESS FOR PRODUCING SAME, AND PROCESS FOR MAKING RELIEF PRINTING PLATE | EIF3L, EIF2B1, EIF2B5 | LMNA 780/4885HTT 4556/4885SMN1; SMN2 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.